European Medicines Agency Grants BioMarin’s Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A

SAN RAFAEL, Calif.: SAN RAFAEL, Calif., May 24, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted its request for accelerated assessment of valoctocogene roxaparvovec, for adults with severe hemophilia A. Accelerated assessment reduces the time frame for the EMA Committee...

Click to view original post